 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Digital rectal examination (DRE) and prostate-specific antigen (PSA) tests can find prostate cancer early, before symptoms develop. In DRE, a doctor inserts a finger into the patient's rectum to feel the prostate. A PSA test is a blood test. Very high PSA levels occur only with prostate cancer, but the more common intermediate levels also occur with benign prostate disease. Abnormal results on DRE or high PSA levels require prostate biopsy to see whether cancer is actually present. To perform the biopsy, doctors insert a hollow needle to obtain a piece of the prostate gland that can be examined under a microscope.
It is not known whether detection and treatment before symptoms develop are helpful to patients. In most cases, prostate cancer grows very slowly, so most men with early prostate cancer die of something else rather than of prostate cancer itself. Early detection, however, puts men at risk for unnecessary worry and side effects of treatment. Surgery and radiation therapy, common treatments for prostate cancer, can cause impotence and urinary leakage.
SUMMARIES FOR PATIENTS
Screening for Prostate Cancer: A Recommendation from the U.S. Preventive Services Task Force
3 December 2002 | Volume 137 Issue 11 | Page I-48
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full reports titled "Screening for Prostate Cancer: Recommendation and Rationale" and "Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force." They are in the 3 December 2002 issue of Annals of Internal Medicine (volume 137, pages 915-916 and pages 917-929). The first report was written by the U.S. Preventive Services Task Force; the second report was written by R Harris and KN Lohr.
What is the U.S. Preventive Services Task Force?
The U.S. Preventive Services Task Force (USPSTF) is a group of health experts that reviews published research and makes recommendations about preventive health care.
What is the problem and what is known about it so far?
The prostate gland is an organ surrounding the tube that empties urine from the bladder. Its function is to add fluid and nutrients to semen, the fluid that carries sperm. Prostate cancer is the most common type of cancer and the second most common cause of cancer-related death in U.S. men. However, prostate cancer often grows slowly and never causes a problem.
How did the USPSTF develop these recommendations?
The USPSTF reviewed published research to measure the benefits and harms of screening for prostate cancer.
What did the authors find?
The USPSTF found good evidence that PSA testing can find early prostate cancer. The evidence suggests that PSA testing correctly identifies more men with prostate cancer than DRE. However, no good-quality evidence shows that finding prostate cancer early means that fewer men die of the disease. Men most likely to benefit if screening is effective are those who are 50 to 70 years of age and those who are older than 45 years of age and at higher risk for prostate cancer because they are African American or because they have a father or brother with prostate cancer.
What does the USPSTF suggest that patients do?
The USPSTF does not recommend for or against routine screening for prostate cancer using DRE or PSA testing. Men who are interested in screening for prostate cancer should discuss it with their doctors and, most important, should not be screened without first understanding the potential benefits and harms of early treatment.
What are the cautions related to these recommendations?
As better information about the positive and negative effects of early detection and treatment of prostate cancer becomes available, the USPSTF may revisit this issue.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  W. D. Evans and L. McCormack Applying Social Marketing in Health Care: Communicating Evidence to Change Consumer Behavior Med Decis Making, September 1, 2008; 28(5): 781 - 792. [Abstract] [PDF]
|
|
|
|
 |
|
 U.S. Preventive Services Task Force Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, August 5, 2008; 149(3): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lin, R. Lipsitz, T. Miller, and S. Janakiraman Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force Ann Intern Med, August 5, 2008; 149(3): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Williams-Piehota, L. A. McCormack, K. Treiman, and C. M. Bann Health information styles among participants in a prostate cancer screening informed decision-making intervention Health Educ. Res., June 1, 2008; 23(3): 440 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. McFall, J. Ureda, T. L. Byrd, A. Valdes, P. Morales, D. B. Scott, D. Williams, J. Calderon-Mora, M. E. Casillas, and E. C. Y. Chan What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men Health Educ. Res., May 9, 2008; (2008) cyn018v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Jacobson Transforming Clinical Practice Guidelines Into Legislative Mandates: Proceed With Abundant Caution JAMA, January 9, 2008; 299(2): 208 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Labrecque, F. Legare, and M. Cauchon Rebuttal: Should Canadians be offered systematic prostate cancer screening?: NO Can Fam Physician, July 1, 2007; 53(7): 1140 - 1141. [Full Text] [PDF]
|
|
|
|
|
|
M. Labrecque, F. Legare, and M. Cauchon Refutation: Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: NON Can Fam Physician, July 1, 2007; 53(7): 1142 - 1143. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Singer, D. F. Penson, and G. S. Palapattu PSA Screening and Elderly Men JAMA, March 7, 2007; 297(9): 949 - 949. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Werny, T. Thompson, M. Saraiya, D. Freedman, B. J. Kottiri, R. R. German, and M. Wener Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004 Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Wilt and I. M Thompson Clinically localised prostate cancer BMJ, November 25, 2006; 333(7578): 1102 - 1106. [Full Text] [PDF]
|
|
|
|
|
|
L. C. Walter, D. Bertenthal, K. Lindquist, and B. R. Konety PSA Screening Among Elderly Men With Limited Life Expectancies. JAMA, November 15, 2006; 296(19): 2336 - 2342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. McFall US Men Discussing Prostate-Specific Antigen Tests With a Physician. Ann. Fam. Med, September 1, 2006; 4(5): 433 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kamangar, G. M. Dores, and W. F. Anderson Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World J. Clin. Oncol., May 10, 2006; 24(14): 2137 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Saraiya, B. J. Kottiri, S. Leadbetter, D. Blackman, T. Thompson, M. T. McKenna, and F. L. Stallings Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002 Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2178 - 2182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Sox and C. Mulrow An Editorial Update: Should Benefits of Radical Prostatectomy Affect the Decision To Screen for Early Prostate Cancer? Ann Intern Med, August 2, 2005; 143(3): 232 - 233. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gattellari, N. Donnelly, N. Taylor, M. Meerkin, G. Hirst, and J. E Ward Does 'peer coaching' increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial Fam. Pract., June 1, 2005; 22(3): 253 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Andriole, D. L. Levin, E. D. Crawford, E. P. Gelmann, P. F. Pinsky, D. Chia, B. S. Kramer, D. Reding, T. R. Church, R. L. Grubb, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial J Natl Cancer Inst, March 16, 2005; 97(6): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer and R. Weissleder Molecular Imaging in the Clinical Arena JAMA, February 16, 2005; 293(7): 855 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Brenner and V. Arndt Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis J. Clin. Oncol., January 20, 2005; 23(3): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wilding and P. Remington Period Analysis of Prostate Cancer Survival J. Clin. Oncol., January 20, 2005; 23(3): 407 - 409. [Full Text] [PDF]
|
|
|
|
|
|
O. W. Brawley and B. S. Kramer Cancer Screening in Theory and in Practice J. Clin. Oncol., January 10, 2005; 23(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Parnes, I. M. Thompson, and L. G. Ford Prevention of Hormone-Related Cancers: Prostate Cancer J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Y. Chan, S. W. Vernon, C. Ahn, and A. Greisinger Do Men Know That They Have Had a Prostate-Specific Antigen Test? Accuracy of Self-Reports of Testing at 2 Sites Am J Public Health, August 1, 2004; 94(8): 1336 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rychetnik, P. Hawe, E. Waters, A. Barratt, and M. Frommer A glossary for evidence based public health J. Epidemiol. Community Health, July 1, 2004; 58(7): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Kuller, A. Thomas, G. Grandits, and J. D. Neaton Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 373 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. N. Lohr Rating the strength of scientific evidence: relevance for quality improvement programs Int. J. Qual. Health Care, February 1, 2004; 16(1): 9 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. S. Kunkel, B. Meyer, C. Daskalakis, J. Cocroft, K. Jennings-Dozier, and R. E. Myers Behaviors Used by Men to Protect Themselves against Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 78 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Robertson Screening for Prostate Cancer Ann Intern Med, September 16, 2003; 139(6): 531 - 532. [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. F. Col The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant? Med Decis Making, September 1, 2003; 23(5): 441 - 448. [Abstract] [PDF]
|
|
|
|
|
|
J. M. McWilliams, A. M. Zaslavsky, E. Meara, and J. Z. Ayanian Impact of Medicare Coverage on Basic Clinical Services for Previously Uninsured Adults JAMA, August 13, 2003; 290(6): 757 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Sorum, J. Shim, G. Chasseigne, S. Bonnin-Scaon, J. Cogneau, and E. Mullet Why do Primary Care Physicians in the United States and France Order Prostate-Specific Antigen Tests for Asymptomatic Patients? Med Decis Making, July 1, 2003; 23(4): 301 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 T. J Wilt Radical prostatectomy reduced death from prostate cancer but not all cause mortality Evid. Based Med., March 1, 2003; 8(2): 41 - 41. [Full Text] [PDF]
|
|
|
|
 |
|
 Screening for Prostate Cancer: Insufficient Evidence Journal Watch (General), January 10, 2003; 2003(110): 1 - 1. [Full Text]
|
|
|
|
|
|
U.S. Preventive Services Task Force* Screening for Prostate Cancer: Recommendation and Rationale Ann Intern Med, December 3, 2002; 137(11): 915 - 916. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
